Literature DB >> 22485083

Optimizing infliximab therapy for inflammatory bowel disease- the tools are getting sharper.

Marie-France Dubeau1, Subrata Ghosh.   

Abstract

Entities:  

Year:  2012        PMID： 22485083      PMCID： PMC3317513     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  16 in total

1.  The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.

Authors:  Shomron Ben-Horin; Miri Yavzori; Lior Katz; Uri Kopylov; Orit Picard; Ella Fudim; Daniel Coscas; Simon Bar-Meir; Itamar Goldstein; Yehuda Chowers
Journal:  Gut       Date:  2010-06-02       Impact factor: 23.059

2.  A Crohn's disease patient who does not respond to infliximab: what is next?

Authors:  Nitsan Maharshak; Scott E Plevy
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-06       Impact factor: 11.382

3.  Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.

Authors:  Uri Kopylov; Yoav Mazor; Miri Yavzori; Ella Fudim; Lior Katz; Daniel Coscas; Orit Picard; Yehuda Chowers; Rami Eliakim; Shomron Ben-Horin
Journal:  Inflamm Bowel Dis       Date:  2011-10-29       Impact factor: 5.325

4.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

5.  Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

Authors:  A A Fasanmade; O J Adedokun; A Olson; R Strauss; H M Davis
Journal:  Int J Clin Pharmacol Ther       Date:  2010-05       Impact factor: 1.366

6.  Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.

Authors:  Benjamin Pariente; Guillaume Pineton de Chambrun; Roman Krzysiek; Marine Desroches; Gauthier Louis; Chiara De Cassan; Clotilde Baudry; Jean-Marc Gornet; Pierre Desreumaux; Dominique Emilie; Jean-Frédéric Colombel; Matthieu Allez
Journal:  Inflamm Bowel Dis       Date:  2011-08-29       Impact factor: 5.325

7.  Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.

Authors:  Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Ole Østergaard Thomsen; Mark Andrew Ainsworth
Journal:  Scand J Gastroenterol       Date:  2010-11-18       Impact factor: 2.423

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 9.  Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review.

Authors:  Andrea Cassinotti; Simon Travis
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

10.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.

Authors:  C H Seow; A Newman; S P Irwin; A H Steinhart; M S Silverberg; G R Greenberg
Journal:  Gut       Date:  2010-01       Impact factor: 23.059
View more
  1 in total

Review 1.  Can molecular stratification improve the treatment of inflammatory bowel disease?

Authors:  Claire Wang; Hannah M Baer; Daniel R Gaya; Robert J B Nibbs; Simon Milling
Journal:  Pharmacol Res       Date:  2019-09-03       Impact factor: 7.658
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.